§ 660.2 General requirements. ( a ) *Processing.* The processing method shall be one that has been shown to consistently yield a specific and potent final product free of properties which would adversely affect the test results when the product is tested by the methods recommended by the manufacturer in the package enclosure.
( b ) *Ancillary reagents and materials.* All ancillary reagents and materials supplied in the package with the product shall meet generally accepted standards of purity and quality and shall be effectively segregated and otherwise manufactured in a manner (such as heating at 60 °C. for 10 hours) that will reduce the risk of contaminating the product and other biological products. Ancillary reagents and materials accompanying the product which are used in the performance of the test as described by the manufacturer's recommended test procedures shall have been shown not to adversely affect the product within the prescribed dating period.
( c ) *Labeling.* ( 1 ) In addition to the items required by other applicable labeling provisions of this subchapter, the following shall also be included: ( i ) Indication of the source of the product immediately following the proper name on both the final container and package label, *e.g.,* human, guinea pig.
( ii ) Name of the test method(s) recommended for the product on the package label and on the final container label when capable of bearing a full label (see § 610.60(a) of this chapter).
( iii ) A warning on the package label and on the final container label if capable of bearing a full label (see § 610.60(a) of this chapter) indicating that the product and antigen if supplied, shall be handled as if capable of transmitting hepatitis.
( iv ) If the product is dried, the final container label shall indicate “Reconstitution date: ___” and a statement indicating the period within which the product may be used after reconstitution.
( v ) The package shall include a package enclosure providing: ( A ) Adequate instructions for use;
( B ) A description of all recommended test methods; and
( C ) Warnings as to possible hazards, including hepatitis, in handling the product and any ancillary reagents and materials accompanying the product.
( 2 ) The applicant may provide the labeling information referenced in paragraph (c)(1) of this section in the form of: ( i ) A symbol accompanied by explanatory text adjacent to the symbol;
( ii ) A symbol not accompanied by adjacent explanatory text that: ( A ) Is contained in a standard that FDA recognizes under its authority in section 514(c) of the Federal Food, Drug, and Cosmetic Act;
( B ) Is used according to the specifications for use of the symbol set forth in FDA's section 514(c) recognition; and
( C ) Is explained in a paper or electronic symbols glossary that is included in the labeling for the device and the labeling on or within the package containing the device bears a prominent and conspicuous statement identifying the location of the symbols glossary that is written in English or, in the case of articles distributed solely in Puerto Rico or in a Territory where the predominant language is one other than English, the predominant language may be used; or
( iii ) A symbol not accompanied by adjacent explanatory text that: ( A ) Is established in a standard developed by a standards development organization (SDO);
( B ) Is not contained in a standard that is recognized by FDA under its authority in section 514(c) of the Federal Food, Drug, and Cosmetic Act or is contained in a standard that is recognized by FDA but is not used according to the specifications for use of the symbol set forth in FDA's section 514(c) recognition;
( C ) Is determined by the manufacturer to be likely to be read and understood by the ordinary individual under customary conditions of purchase and use in compliance with section 502(c) of the Federal Food, Drug, and Cosmetic Act;
( D ) Is used according to the specifications for use of the symbol set forth in the SDO-developed standard; and
( E ) Is explained in a paper or electronic symbols glossary that is included in the labeling for the device and the labeling on or within the package containing the device bears a prominent and conspicuous statement identifying the location of the symbols glossary that is written in English or, in the case of articles distributed solely in Puerto Rico or in a Territory where the predominant language is one other than English, the predominant language may be used.
( 3 ) The use of symbols to provide the labeling information referenced in paragraph (c)(1) of this section which do not meet the requirements of paragraph (c)(2) of this section renders a device misbranded under section 502(c) of the Federal Food, Drug, and Cosmetic Act.
( 4 ) For purposes of paragraph (c)(2) of this section: ( i ) An SDO is an organization that is nationally or internationally recognized and that follows a process for standard development that is transparent, (*i.e.,* open to public scrutiny), where the participation is balanced, where an appeals process is included, where the standard is not in conflict with any statute, regulation, or policy under which FDA operates, and where the standard is national or international in scope.
( ii ) The term “symbols glossary” means a compiled listing of: ( A ) Each SDO-established symbol used in the labeling for the device;
( B ) The title and designation number of the SDO-developed standard containing the symbol;
( C ) The title of the symbol and its reference number, if any, in the standard; and
( D ) The meaning or explanatory text for the symbol as provided in the FDA recognition or, if FDA has not recognized the standard or portion of the standard in which the symbol is located or the symbol is not used according to the specifications for use of the symbol set forth in FDA's section 514(c) recognition, the explanatory text as provided in the standard.
( d ) *Final container.* A final container shall be sufficiently transparent to permit visual inspection of the contents for presence of particulate matter and increased turbidity. The effectiveness of the contents of a final container shall be maintained throughout its dating period.
( e ) *Date of manufacture.* The date of manufacture of Antibody to Hepatitis B surface Antigen that has been iodinated with radioactive iodine (125I) shall be the day of labeling the antibody with the radionuclide.
( f ) *Retention samples.* Each manufacturer shall retain representative samples of the product in accordance with § 600.13 of this chapter except for that which has been iodinated with radioactive iodine. Retention samples of Antibody to Hepatitis B Surface Antigen iodinated with125I shall consist of a minimum of two complete finished packages of each lot of the diagnostic test kit and shall be retained for a period of at least 90 days from the date of manufacture.
[38 FR 32098, Nov. 20, 1973, as amended at 40 FR 29711, July 15, 1975; 46 FR 36134, July 14, 1981; 49 FR 1684, Jan. 13, 1984; 81 FR 38924, June 15, 2016]